Analytical Chemistry, Department of Chemistry - BMC, Uppsala University, Uppsala, Sweden.
J Pharm Biomed Anal. 2013 Jul-Aug;81-82:187-92. doi: 10.1016/j.jpba.2013.04.009. Epub 2013 Apr 18.
The primary production site of erythropoietin (EPO) is shifted from the liver to the kidney shortly after birth. Under conditions of lost or reduced kidney production, it is valuable to measure the production capacity of the liver. However, there is a lack of urine or serum based methods that can distinguish endogenous EPO produced in different cell types. Here is presented a method based on chromatographic interaction with the lectin wheat germ agglutinin (WGA) that can distinguish presumably liver-produced EPO, found in anaemic patients receiving epoetin and darbepoetin, from kidney-produced EPO found in healthy individuals. All the tested samples from haemodialysis patients with end-stage renal disease showed a presence of liver EPO. In some samples, the liver-produced EPO made up 90-100% of total EPO at a concentration of 8-10 ng/L in urine, which indicates that the liver has a quite high production capacity, although not adequate for the degree of anaemia. This glycoform analysis has made it possible to affirm that some anaemic patients can increase their liver-production of EPO. The use of such a method can give better insight into the regulation of non-renal endogenous EPO production, a potential source of EPO intended to replace administration of exogenous EPO.
促红细胞生成素（EPO）的主要产生部位在出生后不久便由肝脏转移到肾脏。在肾脏丧失或减少产生 EPO 的情况下，衡量肝脏的产生能力就显得很有价值。然而，目前缺乏能够区分不同细胞类型产生的内源性 EPO 的尿或血清检测方法。本研究提出了一种基于与凝集素麦胚凝集素（WGA）相互作用的色谱方法，可以区分接受促红细胞生成素和达贝泊汀治疗的贫血患者中可能由肝脏产生的 EPO，以及健康个体中由肾脏产生的 EPO。所有接受终末期肾病血液透析的患者样本均显示存在肝脏 EPO。在一些样本中，在浓度为 8-10ng/L 的尿液中，肝脏产生的 EPO 占总 EPO 的 90-100%，这表明肝脏具有相当高的产生能力，尽管不足以纠正贫血程度。这种糖型分析使我们能够肯定一些贫血患者可以增加肝脏 EPO 的产生。这种方法的使用可以更好地了解非肾脏内源性 EPO 产生的调节，这是一种替代外源性 EPO 给药的潜在 EPO 来源。
